Effect of Complex Weight-reducing Interventions on Rhythm Control in Obese Subjects With Atrial Fibrillation (HOBIT-FS)
Primary Purpose
Atrial Fibrillation, Obesity
Status
Recruiting
Phase
Not Applicable
Locations
Czechia
Study Type
Interventional
Intervention
Physician-lead complex program of weight-reducing interventions
Bariatric surgery - sleeve gastrectomy
Sponsored by
About this trial
This is an interventional treatment trial for Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria:
- Paroxysmal or persistent AF scheduled for primary RF ablation
- BMI ≥30 kg/m2
- Age 18-70 years
- Informed consent to the study
Exclusion Criteria:
- Previous ablation for AF
- Myocardial infarction, stroke or pulmonary embolism < 3 months prior to inclusion
- left ventricular ejection fraction < 40%
- Left atrium diameter > 55 mm
- Active thyroid disease
- Chronic kidney disease stage IV-V (eGFR < 0.5 ml/s)
- Chronic liver disease
- Active malignancy
- Inability to comply with study procedures
Sites / Locations
- Institute for Clinical and Experimental MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Interventional
Conservative
Arm Description
Physician-lead complex program of weight-reducing interventions including education, diet counselling and regular physical activity aimed at achieving and maintaining a 10% reduction of baseline body weight. Bariatric surgery - sleeve gastrectomy in a subgroup of subjects with BMI > 35 kg/m2, i.e. standard indication of bariatric surgery (patients with BMI > 35 kg/m2 and a presence of metabolic or other complications).
Routine treatment of obesity
Outcomes
Primary Outcome Measures
Atrial fibrillation burden
Atrial fibrillation burden expressed as % of total monitoring time at final visit
Secondary Outcome Measures
Number of AF episodes on 14-day Holter monitoring
Number of AF episodes on 14-day Holter monitoring
Progressive reduction of AF burden between 12- and 18-month follow up visit
Progressive reduction of AF burden between 12- and 18-month follow up visit
hsCRP
Epicardial adipose tissue volume
Assessed by transthoracic echocardiography
Concentration of atrial natriuretic peptide (ANP)
Concentration of brain natriuretic peptide (BNP)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04560387
Brief Title
Effect of Complex Weight-reducing Interventions on Rhythm Control in Obese Subjects With Atrial Fibrillation
Acronym
HOBIT-FS
Official Title
Effect of Complex Weight-reducing Interventions on Rhythm Control in Obese Subjects With Atrial Fibrillation
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Recruiting
Study Start Date
September 21, 2020 (Actual)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
June 30, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Martin Haluzik
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obesity is a well-established risk factor for the development of atrial fibrillation (AF), while the reduction of body weight was shown to reduce the risk of AF. However, little is known about the effect of different weight-reducing interventions on AF burden. The study will evaluate the effect of a complex program aimed at weight reduction on AF burden in subjects after catheter ablation for AF and at least 1st degree obesity. This will be investigated in randomized study design and compared with patients receiving standard care without specific obesity-related intervention. The weight loss program will consist of diet, lifestyle and exercise counselling and, in selected subjects, also bariatric surgery in order to achieve a sustained weight loss of >10% of initial body weight. Secondary aims include identification of patient phenotypes with the most benefits from weight reduction as well as elucidation of potential pathomechanisms linking obesity and AF, with the main focus being on low-grade inflammation. The project will help to define the optimal weight-reducing regimen in AF and to tailor the interventions to individual patient needs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Interventional
Arm Type
Experimental
Arm Description
Physician-lead complex program of weight-reducing interventions including education, diet counselling and regular physical activity aimed at achieving and maintaining a 10% reduction of baseline body weight.
Bariatric surgery - sleeve gastrectomy in a subgroup of subjects with BMI > 35 kg/m2, i.e. standard indication of bariatric surgery (patients with BMI > 35 kg/m2 and a presence of metabolic or other complications).
Arm Title
Conservative
Arm Type
No Intervention
Arm Description
Routine treatment of obesity
Intervention Type
Behavioral
Intervention Name(s)
Physician-lead complex program of weight-reducing interventions
Intervention Description
A structured motivational and goal directed program will be used for weight reduction involving physicians, nutritionists, educators and physiotherapists. Initially, based on the input data provided by the patient an individual nutritional plan will be designed with the aim of reducing caloric intake by 10%. Low-intensity aerobic exercise for 30 min will be prescribed 3-times a week with the aim of increasing the frequency to 5-times a week and participants will be offered the possibility to participate in regular physiotherapist-lead group exercises. Patients will be required to maintain a diet and physical activity diary. Regular reviews will be scheduled every 3-6 months according to the actual weight loss.
Intervention Type
Procedure
Intervention Name(s)
Bariatric surgery - sleeve gastrectomy
Intervention Description
Bariatric surgery will be performed based on actual medical indication and independently of patient's participation in the study. Sleeve gastrectomy was selected as the currently most frequent restrictive type of bariatric surgery with a proven efficacy on weight reduction, metabolic status and low-grade inflammation
Primary Outcome Measure Information:
Title
Atrial fibrillation burden
Description
Atrial fibrillation burden expressed as % of total monitoring time at final visit
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Number of AF episodes on 14-day Holter monitoring
Description
Number of AF episodes on 14-day Holter monitoring
Time Frame
18 months
Title
Progressive reduction of AF burden between 12- and 18-month follow up visit
Description
Progressive reduction of AF burden between 12- and 18-month follow up visit
Time Frame
18 months
Title
hsCRP
Time Frame
18 months
Title
Epicardial adipose tissue volume
Description
Assessed by transthoracic echocardiography
Time Frame
18 months
Title
Concentration of atrial natriuretic peptide (ANP)
Time Frame
18 months
Title
Concentration of brain natriuretic peptide (BNP)
Time Frame
18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Paroxysmal or persistent AF scheduled for primary RF ablation
BMI ≥30 kg/m2
Age 18-70 years
Informed consent to the study
Exclusion Criteria:
Previous ablation for AF
Myocardial infarction, stroke or pulmonary embolism < 3 months prior to inclusion
left ventricular ejection fraction < 40%
Left atrium diameter > 55 mm
Active thyroid disease
Chronic kidney disease stage IV-V (eGFR < 0.5 ml/s)
Chronic liver disease
Active malignancy
Inability to comply with study procedures
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kristyna Stolbova, MD
Phone
+420 728 375 528
Email
kristyna.stolbova@ikem.cz
Facility Information:
Facility Name
Institute for Clinical and Experimental Medicine
City
Prague
ZIP/Postal Code
14021
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Haluzik, Prof. DSc.
Phone
+420261361111
Email
martin.haluzik@ikem.cz
12. IPD Sharing Statement
Citations:
PubMed Identifier
33710588
Citation
Stolbova K, Novodvorsky P, Jakubikova I, Dvorakova I, Mraz M, Wichterle D, Kautzner J, Haluzik M. Effect of Complex Weight-Reducing Interventions on Rhythm Control in Obese Individuals with Atrial Fibrillation Following Catheter Ablation: A Study Protocol. Adv Ther. 2021 Apr;38(4):2007-2016. doi: 10.1007/s12325-021-01667-0. Epub 2021 Mar 12.
Results Reference
derived
Learn more about this trial
Effect of Complex Weight-reducing Interventions on Rhythm Control in Obese Subjects With Atrial Fibrillation
We'll reach out to this number within 24 hrs